Whether bevacizumab represents a feasible option for the first-line treatment of unfit and elderly patients with metastatic colorectal cancer remains controversial. The present meta-analysis included data from 782 patients and provides evidence for the clinical benefit yielded in terms of progression-free survival and overall survival by the addition of bevacizumab to first-line fluoropyrimidine-based chemotherapy for these complex patients. Background: Whether bevacizumab represents a feasible option for the first-line treatment of unfit and elderly patients with metastatic colorectal cancer (mCRC) remains controversial. The present systematic review and metaanalysis evaluated the efficacy and safety data of bevacizumab combined with first-line fluoropyrimidine monochemotherapy for these complex patients. Patients and Methods: A systematic search of the published data was conducted through May 31, 2016. The random-effects model was used to combine the effect estimates and the I 2 index to quantify the between-study heterogeneity unexplained by sampling error. Results: We included 3 randomized controlled trials, 4 single-arm phase II trials, and 1 prospective cohort study in the present meta-analysis (n ¼ 782). The monochemotherapy administered was capecitabine in 531 patients (67.9%) and 5-fluorouracil in 251 (32.1%); 500 (63.9%) also received bevacizumab. The median age was 75 years, 441 patients (56.4%) were men, and the Eastern Cooperative Oncology Group performance status was 0 to 1 in 684 patients (87.7%). The combination with bevacizumab produced advantages in terms of both progression-free survival (hazard ratio, 0.52; 95% confidence interval, 0.43-0.64; P < .00001; I 2 ¼ 0%) and overall survival (HR, 0.79; 95% CI, 0.64-0.98; P ¼ .03; I 2 ¼ 0%). The pooled effect estimates of the randomized controlled trials have been previously reported. As expected, all-grade hypertension (27% vs. 4.9%), bleeding (24% vs. 6.4%), thromboembolic events (10% vs. 5%), and proteinuria (25.6% vs. 8.2%) were more frequent in the bevacizumab combination group. Conclusion: Adding bevacizumab to first-line fluoropyrimidine monochemotherapy significantly improved progression-free and overall survival in unfit and elderly patients with mCRC, with a manageable safety profile and no unexpected toxicities.
Introduction
With a median age of diagnosis of > 70 years and more than one third of all deaths occurring in patients aged > 80 years, colorectal cancer (CRC) is predominantly a disease of the elderly. 1 Although systemic treatment has markedly evolved in recent years, how to best approach geriatric or unfit populations remains a matter of debate, with specific guidelines lacking. A widespread use of the geriatric assessment has been advocated to improve patient selection; however, evidence of its value in the decision-making process is limited. 2 [3] [4] [5] [6] Hence, the upfront use of single-agent fluoropyrimidine, given either intravenously or orally, 7 can still be considered a valid option for frail, highly comorbid, or very old patients. Nevertheless, the upfront use of doublet chemotherapy with 5-FU coupled with irinotecan or oxaliplatin has been shown to be as effective for older patients as for younger subjects. 8, 9 However, the prescription of a combination in clinical practice has been often restrained owing to the potential for an increased risk of toxicity. 10, 11 Bevacizumab, the first recombinant humanized monoclonal antibody to vascular endothelial growth factor, is commonly used in CRC in first-and second-line therapy and between treatment lines. A more rational use of the antiangiogenic strategy in the older or unfit population has also been proposed 12 based on results of community-based registries, phase II studies, and a large, randomized phase III trial. 13 Accordingly, subgroup analyses from randomized trials have suggested a similar benefit when adding bevacizumab to chemotherapy for older or younger patients and have not recommended using age alone as a specific criterion to exclude patients from antiangiogenic treatment. Similarly, frail or unfit patients with mCRC might still benefit from doublet chemotherapy regimens. 14 Notwithstanding this large body of evidence, both chemotherapy usage and biologic prescriptions decrease for patients of advanced age. 15, 16 The aim of the present trial-level meta-analysis was to evaluate the effect of adding bevacizumab to the most frequently used cytotoxic regimens for mCRC patients who had been judged unfit to receive an intense upfront treatment (because of age or frailty) and to estimate the magnitude of this effect.
Patients and Methods

Types of Studies, Participants, Interventions, and Outcomes
We included randomized controlled trials (RCTs) or prospective cohort studies of patients with advanced or metastatic CRC. We restricted the data to patients receiving monochemotherapy plus bevacizumab because of advanced age or comorbidity. Data on the following outcome measures were studied: objective response rate (ORR), progression-free survival (PFS), and overall survival (OS).
Search Strategy and Selection Criteria
The PubMed and EMBASE databases were searched for RCTs and prospective cohort studies in May 31, 2016 . For EMBASE, the query was "bevacizumab"/exp OR "bevacizumab" AND ("aged"/exp OR "aged" OR "elderly"/exp OR "elderly" OR "unfit") AND ("colorectal tumor"/exp OR "colorectal tumor" OR "colorectal carcinoma"/exp OR "colorectal carcinoma" OR "colorectal neoplasm"/exp OR "colorectal neoplasm" OR "colorectal cancer"/exp OR "colorectal cancer") AND [embase]/lim NOT [medline]/lim.
Ongoing studies and studies with < 10 patients per arm were excluded.
Data Extraction
Two investigators (V.T., L.P.) independently screened the titles and abstracts for inclusion. Full reports were retrieved for further assessment if the information in the abstract suggested that the study met all the prespecified criteria.
Two investigators (V.T., L.P.) were responsible for data assessment and extraction. Details on the study design, participants, setting, interventions, quality components, and efficacy and safety outcomes were recorded. Any inconsistency was resolved by discussion (F.P., G.M.).
For studies included in > 1 publication, the data were extracted from all the publications. However, we considered the final or updated version of each trial as the primary reference. We included trials in which patients crossed-over to the other treatment arm at progression or received other treatment off-study and were analyzed according to the arm to which they had been originally randomized. We also extracted data from patient subgroups if these answered our original question.
Statistical Analysis
The measure of association for PFS and OS was expressed as the hazard ratio (HR). The measure of association for the ORR was the odds ratio (OR). The estimation of the median time to PFS and OS was calculated using the weighted average of the hazard rate with the weights calculated by the inverse variance approach. The hazard rate and its standard error were estimated using the median time as the denominator under the assumption of exponential distribution. The I 2 index was calculated to estimate the heterogeneity among trials. The random effects model was used for estimating and testing results in all analyses.
Although the efficacy analyses included data from RCTs, the safety analysis also incorporated data from cohort studies. The determination of toxicity (all National Cancer Institute Common Terminology Criteria for Adverse Events grades and grade 3-4) focused on the main class of toxicities involving chemotherapy and bevacizumab: hematologic, cardiovascular, and renal toxicity and e62 -Clinical Colorectal Cancer June 2017
Bevacizumab Plus Fluoropyrimidines for Unfit or Older mCRC Patients hypertension and bleeding. The quality of the RCTs was independently evaluated by 2 of us (V.T., L.P.) using the approach proposed by the Cochrane Collaboration for experimental studies; the most conservative rate was considered for each item. The metaanalysis was performed using Revman, version 5.2. The present work was conducted and reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines for the reporting of systematic reviews and meta-analyses. 17 
Results
Published Data Search Results and Study Population
The PubMed and EMBASE database search produced 1714 studies published until May 31, 2016. After exclusion of duplicates and irrelevant studies, 8 reports were deemed to be eligible for the meta-analysis (Figure 1) . 13, [18] [19] [20] [21] [22] [23] [24] Of the 8 studies, 3 were multicenter RCTs (n ¼ 558) 13, 18, 19 and 5 were phase II or prospective series (n ¼ 224). [20] [21] [22] [23] [24] The characteristics of the studies included are reported in Supplemental Figure 2A ).
All trials provided data for PFS and OS. 13, [18] [19] [20] [21] [22] [23] [24] The weighted pooled median PFS was 9.4 months (95% CI, 8.2-11.2 months) with the bevacizumab combinations (P for heterogeneity ¼ .55; I 2 ¼ 0%) and ranged from 5.1 to 5.5 months in the 2 control arms with data available. 13, 19 Bevacizumab-based doublets reduced the risk of progression by approximately 50% compared with Figure 2B ). In contrast, the weighted pooled median OS in the bevacizumab arms was 20.4 months (95% CI, 17.3-24.8 months; P for heterogeneity ¼ .85; I 2 ¼ 0%) and ranged from 12.9 to 16.8 months in the 2 control arms with data available. 13, 19 The addition of bevacizumab to chemotherapy reduced the risk of death by approximately 20% (HR, 0.79; 95% CI, 0.64-0.98; P ¼ .03; P for heterogeneity ¼ 1.00, I 2 ¼ 0%; Figure 2C ).
Compliance and Safety
The treatment regimens are reported in Supplemental Table 3 (available in the online version). The reasons for discontinuation in the bevacizumab arms were mainly disease progression (48.2%), toxicity (21.2%), and refusal (11.4%). 13, 20, 22, 24 In the control arms, the corresponding values were 66.2%, 9.8%, and 6.8%. 13 Toxicity was reported as the reason for treatment discontinuation in the bevacizumab arms for 25.4% of the patients in the nonrandomized studies 20, 22, 24 and 17.6% of those in the randomized trials. 13 In the safety analysis (Table 2) , which included 75% of all patients (6 trials), 13, [19] [20] [21] [22] [23] the main all-grade toxicities were hand-foot syndrome (57.4%), diarrhea (42.1%), and hypertension (27%) in the bevacizumab arms and hand-foot syndrome (38.6%), diarrhea (34.3%), and nausea (26.4%) in the monochemotherapy-alone arms. Among the severe toxicities (grade 3-4; Table 3 ), the more frequent were hand-foot syndrome (16.3%), diarrhea (15.7%), and venous thrombosis (7.4%) in the bevacizumab arms and diarrhea (19.5%), hand-foot syndrome (6.4%), and venous thrombosis (4.3%) in control arms. The rates of grade 3-4 hypertension were greater among the bevacizumab-treated patients (6.9% vs. 2%).
The adverse events typically observed with bevacizumab therapy, such as bleeding and proteinuria (all grades), were also more frequent with bevacizumab than with chemotherapy alone (24.3% vs. 6.4% and 25.6% vs. 8.2%, respectively). Grade 3 to 4 hematologic toxicity was rare.
Modification of the chemotherapy was reported rarely. In the largest phase III trial (Avastin With Xeloda in the Elderly [AVEX]), 13 the capecitabine dose modification rate was 54% and 43% in the experimental and control arms, respectively. The dose intensity for the combination arms was generally good when reported, for both chemotherapy (range, 84%-94%) and bevacizumab (99%) in the 5 arms with data available. 13, 18, 19, 21, 22 A similar dose intensity was reported in the 3 fluoropyrimidine arms.
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Risk of Bias Assessment
The risk of bias was evaluated on the PFS endpoint, which was less accurate than the OS endpoint. A selection bias could not be excluded in 1 of the 3 RCTs because of inadequate reporting. 18 For the same reason, an attrition bias could not be excluded in 2 of the 3 RCTs. 18, 19 All review authors (V.T., L.P., F.P., G.M.) independently assessed a high risk of detection bias for each RCT because of the absence of blinding 13, 18 or inadequate reporting of applied statistical methods. 19 Details regarding the risk of bias are shown in Figure 3 .
Discussion
We performed the present analysis in the attempt to understand the feasibility, safety, and efficacy of the combination of bevacizumab with fluoropyrimidines in elderly or unfit patients with mCRC. The treatment of these patients is a common challenge in clinical practice, because a worldwide accepted therapeutic standard is still lacking. It is well known that elderly and unfit patients are generally excluded or underrepresented in RCTs. 25 Furthermore, the elderly patients included in clinical trials are typically a selected group of subjects with favorable clinical features; therefore, they are not fully representative of the patients seen in real-world clinical practices. Moreover, elderly and unfit patients are a heterogeneous group of subjects with as yet undefined rigorous criteria for age cutoffs and comorbidity assessments. Therefore, elderly patients are commonly treated with a very conservative approach for the fear of excessive toxicities or complications related to medical therapies. 26 To date, monochemotherapy combined with fluoropyrimidines (5-FU or capecitabine) is one of the most commonly used treatments. 27 Retrospective data have shown that in elderly or unfit patients, the use of bevacizumab is usually limited compared with that use in a younger population. This is mainly because clinicians are concerned about possible cardiovascular toxicities, although several trials have indicated the significant benefit afforded by the addition of bevacizumab to fluoropyrimidines compared with fluoropyrimidines alone. 16, 28 Therefore, the aim of the present meta-analysis was to only select trials reporting data for elderly or unfit patients treated with a backbone chemotherapy of fluoropyrimidines alone combined with bevacizumab. Our results demonstrated clinically meaningful improvements in terms of activity and efficacy provided by the addition of bevacizumab to fluoropyrimidines. The weighted ORR was 33.3%. Also, by pooling the data from the RCTs, the OR for progression was 2.05 in favor of bevacizumab (P ¼ .004). The overall-weighted PFS was 9.4 months. By pooling the data from the RCTs, the HR for progression was 0.52 in favor of bevacizumab (P < .001). Finally, the weighted OS was 20.4 months; by pooling the RCT data, the HR for death was 0.64 in favor of bevacizumab (P ¼ .03). We believe these findings are not only statistically significant but also relevant from a clinical viewpoint for this population of patients with unfavorable medical features.
The safety profile seems acceptable and manageable. The increase in all-grade toxicities was not surprising, and the incidence of grade 3-4 toxicity was only slightly increased by the addition of bevacizumab. In particular, the frequency of clinically harmful toxicities (eg, arterial thrombosis, myocardial infarction, gastrointestinal perforation, and bleeding) ranged from 1% to 2%. Furthermore, no Our analysis had several limitations. First, our study was not a pooled analysis of raw data from individual patients but a metaanalysis of summary statistics of published data. Therefore, the heterogeneity of trial design, patient inclusion criteria, and treatment administration should be considered as potential biases. However, to limit this problem, we decided to carefully select the trials to be included in our analysis. In particular, we selected only prospective trials reporting data from elderly or unfit patients treated in first-line with monochemotherapy with 5-FU or capecitabine with or without bevacizumab. Also, we excluded trials of Asian patients. A second limitation lies in the quality of published data in this setting. Despite our careful selection, the criteria for patient accrual were often poorly defined ("patient deemed unsuitable for combination therapy"). Also, the reported data on comorbidity assessment and treatment modulation and discontinuation were sometime incomplete. Once more, in this scenario, it would only be possible to have more robust data by increasing the number of patients analyzed (782 in our pooled analysis). Finally, we reported data derived from the analysis of published trials; therefore, some degree of patient selection was present (ie, Eastern Cooperative Oncology Group performance status was > 1 for only 13% of patients). However, the median age of the subjects included in the analysis was relatively old (75 years), and the frequency of comorbidities was considerable (hypertension in 54%, cardiomyopathy in 30%, diabetes in 20%, vascular accidents in 11%), suggesting that our studied population was the target population as we had planned.
The present analysis showed that bevacizumab added to first-line fluoropyrimidine chemotherapy for elderly or unfit patients with mCRC provides statistically significant and clinically meaningful advantages in ORR, PFS, and OS. Currently, only few data are available regarding upfront treatment of elderly or unfit patients with mCRC using anti-endothelial growth factor receptor agents as monotherapy. 30 The available data from retrospective analyses or small phase II trials 31, 32 are intriguing; however, their results are difficult to translate into daily practice. A randomized study of elderly or unfit patients with mCRC and RAS/BRAF wild-type tumors would be desirable to formally confirm the efficacy of anti-endothelial growth factor receptor agents as single-agent firstline therapy. We believe the optimal selection of first-line treatment in this population is particularly important, because of the limited use of subsequent lines of therapy (the rate of second-line therapies ranged from 37% to 50% in the trials we analyzed). Although the overall incidence of adverse events was slightly increased by the addition of bevacizumab, the safety profile of the treatment did not differ significantly from that of younger patients. Therefore, older age or the presence of some comorbidities should not be considered as an absolute contraindication for the addition of bevacizumab to fluoropyrimidine-based chemotherapy. Moreover, it should be noted that concomitant anticoagulant therapy, if indicated, could be safely administered with bevacizumab. 33 Nevertheless, a careful assessment of the patient's medical history with the identification of clinically relevant comorbidities (in particular, cardiovascular events 6 months before treatment start) and potential risk factors (eg, uncontrolled hypertension, unstable angina, and arrhythmia requiring treatment) is necessary to minimize treatment-related toxicities and increase the therapeutic ratio of treatment.
The strength of our results are potentially limited by the overall quality of the trials conducted in elderly and unfit patients, which was generally quite low owing to several factors, including the relatively low patient number, the equivocal criteria used for the definition of "elderly," and the variable assessment of comorbidities. Further efforts to conduct high-quality prospective trials with elderly or unfit mCRC patients is needed, and it is highly recommended that these trials include a comprehensive geriatric assessment and the evaluation of important endpoints such as changes in functional, mental, and comorbid status and quality of life. In particular, a formal comparison between 5-FU or capecitabine plus bevacizumab and dose-adapted doublet chemotherapy in the geriatric population is warranted. Similarly, it would be interesting to address the comparison between capecitabine plus bevacizumab versus capecitabine and oxaliplatin plus bevacizumab, although the latter combination seems feasible. 34 These comparisons should be prospectively tested in randomized trials, which could include evaluations of the quality of life and pharmacoeconomics aspects. The results of these studies are eagerly awaited by the oncologic community.
Conclusion
The addition of bevacizumab to first-line fluoropyrimidine-based chemotherapy in elderly or unfit patients with mCRC is feasible without particular safety concerns and provides relevant results in terms of both activity and efficacy. This combination should therefore represent an important treatment option for this complex group of patients.
Clinical Practice Points
A therapeutic standard for elderly and unfit patients with mCRC is still lacking. The present meta-analysis tested bevacizumab with fluoropyrimidines as first-line therapy. PFS and OS were significantly increased with the combination of bevacizumab and a fluoropyrimidine. The safety profile was acceptable, without particular concerns. First-line bevacizumab with fluoropyrimidines is feasible for these complex patients.
